Duality Advisers LP Sells 29,846 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Duality Advisers LP lowered its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 69.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 12,828 shares of the medical research company’s stock after selling 29,846 shares during the period. Duality Advisers LP’s holdings in NeoGenomics were worth $208,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BluePath Capital Management LLC bought a new stake in NeoGenomics in the third quarter valued at approximately $30,000. WINTON GROUP Ltd purchased a new position in shares of NeoGenomics during the third quarter valued at approximately $133,000. Corton Capital Inc. purchased a new position in shares of NeoGenomics during the third quarter valued at approximately $141,000. Aigen Investment Management LP purchased a new position in shares of NeoGenomics during the third quarter valued at approximately $163,000. Finally, Mackenzie Financial Corp purchased a new position in shares of NeoGenomics during the third quarter valued at approximately $199,000. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Price Performance

Shares of NASDAQ:NEO opened at $14.14 on Friday. NeoGenomics, Inc. has a 1-year low of $11.03 and a 1-year high of $21.22. The company has a debt-to-equity ratio of 0.57, a quick ratio of 5.95 and a current ratio of 6.20. The business has a fifty day moving average price of $15.04 and a 200-day moving average price of $15.89.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.05. NeoGenomics had a negative return on equity of 4.13% and a negative net margin of 14.87%. The firm had revenue of $155.55 million during the quarter, compared to the consensus estimate of $152.90 million. As a group, analysts anticipate that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Insider Activity at NeoGenomics

In related news, General Counsel Alicia C. Olivo sold 2,587 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $14.96, for a total transaction of $38,701.52. Following the sale, the general counsel now directly owns 34,866 shares of the company’s stock, valued at $521,595.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Needham & Company LLC upped their price target on NeoGenomics from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, February 21st. BTIG Research decreased their price objective on NeoGenomics from $25.00 to $21.00 and set a “buy” rating for the company in a report on Friday, December 29th. The Goldman Sachs Group increased their price objective on NeoGenomics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. TD Cowen decreased their price objective on NeoGenomics from $22.00 to $19.00 and set an “outperform” rating for the company in a report on Friday, December 29th. Finally, Piper Sandler increased their price objective on NeoGenomics from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Monday, February 26th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, NeoGenomics presently has a consensus rating of “Moderate Buy” and an average price target of $19.50.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.